Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134955 | 0.85 | HRH3 (0.41) | MAPTL3MBTL1HRH3 | |
| SCHEMBL6132331 | 0.81 | RAB9A (0.44) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6134375 | 0.80 | HRH3 (0.52) | MAPTKDM4ETP53HSD17B10ALDH1A1 | |
| SCHEMBL6134976 | 0.77 | HDAC3 (0.45) | RAB9ASMN1; SMN2NPC1ALDH1A1HRH3 | |
| SCHEMBL6134435 | 0.76 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL6135361 | 0.76 | HRH3 (0.50) | ALDH1A1HRH3 | |
| SCHEMBL6134693 | 0.75 | MKNK1 (0.41) | HRH3 | |
| SCHEMBL6134689 | 0.74 | CA12 (0.40) | MAPTLMNATP53HRH3 | |
| SCHEMBL6133892 | 0.74 | CSNK2A2 (0.42) | HRH3 | |
| SCHEMBL3107207 | 0.74 | RAB9A (0.76) | RAB9AMAPTLMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | RAB9A 3326/4885MAPT 1629/4885LMNA 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.